- Home
- IRWD
IRWD
Ironwood Pharmaceuticals Inc.
as 03-28-2025 4:00pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2010 |
| Target Price: | $9.75 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.34 - $8.64 | Next Earning Date: | 05-08-2025 |
| Revenue: | $351,410,000 | Revenue Growth: | -20.63% |
| Revenue Growth (this year): | -16.7% | Revenue Growth (next year): | 10.51% |
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| John Minardo | IRWD | Chief Legal Officer | Feb 10 '25 | Sell | $1.76 | 38,938 | $68,530.88 | 408,132 | |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 10 '25 | Sell | $1.76 | 139,064 | $244,752.64 | 1,160,634 | |
| Shetzline Michael | IRWD | SVP, CMO, Head-Res&Drug | Feb 10 '25 | Sell | $1.76 | 41,269 | $72,633.44 | 554,007 | |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 10 '25 | Sell | $1.76 | 12,048 | $21,204.48 | 279,655 | |
| Martini Gregory S. | IRWD | Chief Financial Officer | Feb 10 '25 | Sell | $1.76 | 12,052 | $21,211.52 | 183,810 |
Latest Ironwood Pharmaceuticals Inc. News
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Ironwood Pharmaceuticals Gets Nasdaq Non-Compliance Notice
Business Wire
2 days ago
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
Zacks
4 days ago
Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains?
Insider Monkey
a month ago
Is Ironwood Pharmaceuticals, Inc. (IRWD) the Best Small Cap Pharma Stock to Buy Now?
Zacks
a month ago
IRWD's Q4 Earnings and Revenues Fall Shy of Estimates, Stock Down
GuruFocus.com
a month ago
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Highlights: Strong Prescription ...
Thomson Reuters StreetEvents
a month ago
Q4 2024 Ironwood Pharmaceuticals Inc Earnings Call
Zacks
a month ago
Ironwood Pharmaceuticals (IRWD) Q4 Earnings and Revenues Miss Estimates
Compare IRWD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.